Table 1 Comparison of perioperative variables between cohorts underwent OG or LG
Before propensity score matching | After propensity score matching | |||||
|---|---|---|---|---|---|---|
OG (n=192) | LG (n=189) | p value | OG (n=108) | LG (n=108) | p value | |
Age | 67.9±1.0 | 64.6±1.1 | 0.01 | 67.6±1.3 | 67.8±1.5 | 1.00 |
≧ 70 | 97 (50.5%) | 76 (40.2%) | 0.04 | 53 (49.1%) | 56 (51.9%) | 0.68 |
Sex: male | 135 (70.3%) | 120 (63.5%) | 0.16 | 74 (68.5%) | 69 (63.9%) | 0.47 |
Body mass index | 24.2±0.3 | 24.0±0.2 | 0.48 | 24.4±0.3 | 23.5±0.3 | 0.03 |
Hemoglobin | 11.0±0.2 | 12.4±0.1 | <0.01 | 11.7±0.2 | 11.8±0.2 | 0.96 |
ASA class | 0.66 | 0.30 | ||||
1 | 61 (31.8%) | 52 (27.5%) | 36 (33.3%) | 28 (25.9%) | ||
2 | 97 (50.5%) | 101 (53.4%) | 53 (49.1%) | 53 (49.1%) | ||
3 | 34 (17.7%) | 36 (19.0%) | 19 (17.6%) | 27 (25.0%) | ||
Charlson comorbidity index | 4.7±0.1 | 4.6±0.1 | 0.58 | 4.6±0.2 | 4.9±0.2 | 0.17 |
Prior abdominal surgery | 26 (13.5%) | 35 (18.5%) | 0.19 | 15 (13.9%) | 18 (16.7%) | 0.57 |
Extent of gastrectomy | <0.01 | 1.00 | ||||
Distal gastrectomy | 113 (58.9%) | 142 (75.1%) | 77 (71.3%) | 77 (71.3%) | ||
Total gastrectomy | 79 (41.1%) | 47 (24.9%) | 31 (28.7%) | 31 (28.7%) | ||
Extent of lymphadenectomy | 0.25 | 0.58 | ||||
Less than D2 | 37 (19.3%) | 28 (14.8%) | 19 (17.6%) | 16 (14.8%) | ||
D2 | 155 (80.7%) | 161 (85.2%) | 89 (82.4%) | 92 (85.2%) | ||
Combined organ resection | 41 (21.4%) | 8 (4.2%) | <0.01 | 10 (9.3%) | 8 (7.4%) | 0.62 |
Tumor size (mm) | 52.1±2.0 | 41.9±1.7 | <0.01 | 49.1±2.8 | 48.0±2.4 | 0.85 |
Retrieved lymph nodes | 25.4±1.1 | 30.2±1.1 | <0.01 | 28.7±1.4 | 28.4±1.4 | 0.99 |
Metastatic lymph nodes | 5.1±0.5 | 2.9±0.4 | <0.01 | 3.6±0.5 | 3.6±0.5 | 0.96 |
Closest resection margin | 28.5±1.2 | 34.4±1.1 | <0.01 | 30.6±1.6 | 30.5±1.4 | 0.72 |
Pathologic T stage | <0.01 | 0.17 | ||||
1 | 28 (14.6%) | 69 (36.5%) | 23 (21.3%) | 29 (26.9%) | ||
2 | 27 (14.1%) | 37 (19.6%) | 22 (20.4%) | 18 (16.7%) | ||
3 | 44 (22.9%) | 43 (22.8%) | 23 (21.3%) | 33 (30.6%) | ||
4 | 93 (48.4%) | 40 (21.2%) | 40 (37.0%) | 28 (25.9%) | ||
Pathologic N stage | <0.01 | 0.56 | ||||
0 | 66 (34.4%) | 108 (57.1%) | 50 (46.3%) | 49 (45.4%) | ||
1 | 31 (16.1%) | 28 (14.8%) | 15 (13.9%) | 19 (17.6%) | ||
2 | 40 (20.8%) | 23 (12.2%) | 24 (22.2%) | 17 (15.7%) | ||
3 | 55 (28.6%) | 30 (15.9%) | 19 (17.6%) | BBG | ||
Pathologic stage | <0.01 | 0.68 | ||||
I | 40 (20.8%) | 94 (49.7%) | 35 (32.4%) | 41 (38.0%) | ||
II | 44 (22.9%) | 38 (20.1%) | 25 (23.1%) | 22 (20.4%) | ||
III | 108 (56.3%) | 57 (30.2%) | 48 (44.4%) | 45 (41.7%) | ||
Lymphovascular invasion | 102 (53.1%) | 66 (34.9%) | <0.01 | 51 (47.2%) | 46 (42.6%) | 0.49 |
Extracapsular extension | 72 (37.5%) | 38 (20.1%) | <0.01 | 28 (25.9%) | 28 (25.9%) | 1.00 |
Poor differentiated | 151 (78.6%) | 134 (70.9%) | 0.08 | 77 (71.3%) | 75 (69.4%) | 0.77 |
Adjuvant chemotherapy | 74 (38.5%) | 64 (33.9%) | 0.34 | 36 (33.3%) | 40 (37.0%) | 0.57 |